Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Procainamide-induced agranulocytosis differs serologically and clinically from procainamide-induced lupus.
Clin Immunol Immunopathol
February 1996
Division of Rheumatology, Department of Medicine, University of Washington School of Medicine, Seattle 98108, USA.
Agranulocytosis is a well recognized but uncommon complication of procainamide (PA) therapy, whereas a lupus-like syndrome occurs in approximately 20% of patients treated chronically with PA. In order to gain insight into the immunopathogenic relationships among these conditions, we compared the humoral immune abnormalities in these patient groups as well as in asymptomatic PA-treated patients. A relatively uniform profile of IgM but not IgG autoantibody reactivity with a set of chromatin-related antigens was observed in eight elderly men who developed agranulocytosis after treatment with PA.
View Article and Find Full Text PDFSustained-release procainamide-induced reversible granulocytopenia after myocardial infarction.
Jpn Heart J
July 1995
Second Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
A 71-year-old man with paroxysmal atrial fibrillation who had a previous anterior myocardial infarction exhibited granulocytopenia 8 days following the administration of oral sustained-release procainamide (750 mg/day). The plasma concentrations of procainamide and N-acetyl procainamide were at subtherapeutic levels. Discontinuation of procainamide led to complete recovery.
View Article and Find Full Text PDFNecrotizing epiglottitis in a patient with procainamide-induced neutropenia.
Am J Otolaryngol
April 1994
Department of Otolaryngology and Communicative Disorders, Long Island Jewish Medical Center, New Hyde Park, NY.
Comparative metabolism and covalent binding of procainamide by human leukocytes.
Drug Metab Dispos
March 1992
Faculty of Pharmacy, University of Toronto, Ontario, Canada.
Activated neutrophils and monocytes were found to metabolize procainamide to a reactive hydroxylamine. In contrast, there was little or no metabolism by lymphocytes or platelets. Therefore, it appears that only leukocytes that contain myeloperoxidase can metabolize procainamide to a significant degree.
View Article and Find Full Text PDFN-Chlorination and oxidation of procainamide by myeloperoxidase: toxicological implications.
Chem Res Toxicol
March 1992
Faculty of Pharmacy, University of Toronto, Canada.
In previous studies we had shown that procainamide is metabolized to reactive metabolites by activated leukocytes, and evidence pointed to involvement of myeloperoxidase (MPO). In this study we examine the metabolism of procainamide by MPO/H2O2, in the presence and absence of chloride ion. In the absence of chloride ion, the metabolism was very similar to that seen with activated leukocytes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!